Drug Detail

Information about Ganetespib

Generic Name	Ganetespib
IND	STA-9090
Brand Name (US)
Manufacturer	Synta
Drug Type	HSP90 inhibitor
Delivery	Intravenous
Approval Status	Phase 2
Indications
Overall Strategy	KIT Protein Based
Strategy	Destroy KIT
Drug Category	HSP90 inhibitor

STA-9090 is an HSP-90 inhibitor. According to the Synta press release, in preclinical studies “STA-9090 has shown the ability to inhibit multiple kinases with comparable potency to, and a broader activity profile than specific kinase inhibitors such as Gleevec, Tarceva and Sutent. In addition, STA-9090 has shown potency ten to 100 times greater than the geldanamycin family of Hsp90 inhibitors, as well as activity against a wider range of kinases. In in vivo models, STA-9090 has shown strong efficacy in a wide range of cancer types, including cancers resistant to Gleevec, Tarceva, and Sutent.”
Medical News TODAY reports: "Along with work presented by Dr. Shapiro's lab, we and our collaborators have shown broad activity of STA-9090 against multiple cancer types, including both cancers that are sensitive to kinase inhibitors, such as Gleevec and Sutent, and cancers that are resistant to those kinase inhibitors. These collective results have shown that STA-9090 is differentiated within the Hsp90 inhibitor class, including improved potency and reduced toxicity compared to the 17-AAG family of inhibitors."